Table 5.
Effect of embolic agent on UFS-QoL symptom score and HRQL score
| Embospheres | Gelfoam | Difference between groups (E-G)*** | |||||
|---|---|---|---|---|---|---|---|
| Baseline* | 6 months* | Change** | Baseline* | 6 months* | Change** | ||
| Symptom score | 64 (18) | 23 (16) | −41 (−56 to − 25) p < 0.001 | 54 (15) | 32 (26) | −22 (− 36 to − 8) p = 0.01 | −14 (− 34 to 6) p = 0.15 |
| HRQL | 41 (28) | 79 (20) | 38 (13 to 63) p = 0.01 | 53 (19) | 78 (21) | 25 (9 to 41) p = 0.01 | 2 (−18 to 22) p = 0.84 |
*Mean (SD)
**Mean of change over time calculated as 6 month – baseline, 95% CI of change, p-value
***Mean difference between embolic agents at 6 months adjusted for baseline values, 95% CI of difference. Positive values indicate higher results in the E group